Avoro funds buy 2.39M Scribe Therapeutics shares

Scribe Therapeutics (SCTX) insider filings report that entities associated with Avoro Capital Advisors and Avoro Ventures indirectly purchased 2,391,238 shares of Common Stock.

Rhea-AI Filing Summary

Scribe Therapeutics (SCTX) insider filings report that entities associated with Avoro Capital Advisors and Avoro Ventures indirectly purchased 2,391,238 shares of Common Stock. This includes 2,333,333 shares bought in the IPO at $15.00 per share and additional open‑market purchases at $22.31 and $18.25 per share on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P. The shares are held by these funds, with the reporting persons potentially deemed beneficial owners through advisory and control roles and disclaiming beneficial ownership beyond their pecuniary interest. Total reported indirect holdings include 3,088,888 shares, of which 697,650 arose from the automatic conversion of Series B Preferred Stock into Common Stock upon the IPO closing.

Insider Trade Summary

Net Buyer: 2,391,238 shares

Net Buy 3 txns

Insider Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLC

Role Director, 10% Owner | Director, 10% Owner | Director

Bought 2,391,238 shs ($36.26M)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share F2, F3, F6, F4, F5	7,905	$18.25	$144K
Purchase	Common Stock, par value $0.0001 per share F1, F6, F4, F5	2,333,333	$15.00	$35.00M
Purchase	Common Stock, par value $0.0001 per share F2, F6, F4, F5	50,000	$22.31	$1.12M

Holdings After Transaction: Common Stock, par value $0.0001 per share — 3,088,888 shares (Indirect, See footnotes)

Footnotes (6)

1. F1. The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").
2. F2. The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
3. F3. Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
4. F4. The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
5. F5. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
6. F6. The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

Key Figures

IPO purchase: 2,333,333 shares at $15.00 per share Open-market purchase 1: 50,000 shares at $22.31 per share Open-market purchase 2: 7,905 shares at $18.25 per share +5 more

8 metrics

IPO purchase 2,333,333 shares at $15.00 per share Common Stock purchased from underwriters in the IPO on behalf of Avoro funds

Open-market purchase 1 50,000 shares at $22.31 per share Common Stock purchased in open market on 2026-07-24 for Avoro Life Sciences

Open-market purchase 2 7,905 shares at $18.25 per share Common Stock purchased in open market on 2026-07-28 for Avoro Life Sciences

Total shares bought 2,391,238 shares Aggregate indirect Common Stock purchases reported across the three transactions

Indirect holdings after transactions 3,088,888 shares Total Common Stock held indirectly by Avoro Life Sciences and Avoro Ventures Fund

Series B conversion shares 697,650 shares Common Stock included in holdings, issued upon conversion of Series B Preferred Stock

Conversion ratio one-for-0.1689 Each Series B Preferred share convertible into Common Stock on this basis at IPO closing

Holdings breakdown 2,598,973 and 489,915 shares Common Stock held by Avoro Life Sciences and Avoro Ventures Fund, respectively

Key Terms

initial public offering, beneficial ownership, pecuniary interest, as-converted basis, +2 more

6 terms

initial public offering financial

"shares were purchased from underwriters in the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

beneficial ownership financial

"may be deemed to beneficially own the securities held by the Funds"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest"

as-converted basis financial

"shares were reported on an as-converted basis in the Reporting Persons' Form 3"

As-converted basis means counting securities that can become common stock—like convertible bonds or preferred shares—as if they already were common shares when calculating totals such as shares outstanding, ownership percentages, or per-share metrics. Investors use it to see the potential dilution and the “what-if” size of the shareholder base; it’s like imagining all restaurant coupons have been redeemed so you know how crowded the table could become and how slices of the pie would shrink.

Series B Preferred Stock financial

"shares of the Issuer's Series B Preferred Stock held by the Funds"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Column 5 financial

"Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held"

FAQ

What did SCTX insider Behzad Aghazadeh and Avoro entities report in this Form 4?

They reported indirect purchases of 2,391,238 SCTX common shares through funds they advise or control, including IPO allocations and open-market buys, with total reported indirect holdings of 3,088,888 shares held by Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P.

How many SCTX shares were bought in the IPO according to this Form 4?

The filing states that 2,333,333 SCTX shares were purchased in the IPO at $15.00 per share. Of these, 2,066,666 shares were bought for Avoro Life Sciences Fund LLC and 266,667 shares for Avoro Ventures Fund L.P. as part of the IPO allocation.

What additional open-market SCTX share purchases are disclosed in this Form 4?

The report shows open-market purchases on behalf of Avoro Life Sciences of 50,000 shares at $22.31 and 7,905 shares at $18.25 per share. These transactions were executed as indirect holdings for the fund, not direct personal purchases by the individual filer.

How many SCTX shares do the Avoro funds hold after these transactions?

Total indirect holdings reported are 3,088,888 SCTX common shares, with 2,598,973 held by Avoro Life Sciences and 489,915 by Avoro Ventures Fund. This figure includes shares issued upon conversion of Series B Preferred Stock at the IPO closing.

How did SCTX Series B Preferred Stock factor into the reported holdings?

The filing notes 697,650 SCTX common shares in the total holdings came from conversion of Series B Preferred Stock. Each preferred share converted to common on a one-for-0.1689 basis automatically at the IPO closing, with no separate transaction reported here.

Do the SCTX Form 4 reporting persons claim full beneficial ownership of the Avoro fund shares?

No. The reporting persons state that they may be deemed beneficial owners through advisory and control roles but expressly disclaim beneficial ownership of the securities except to the extent of their pecuniary interest in the funds and managed accounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 10:07 AM Accepted by SEC EDGAR 07/28/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	07/24/2026		P		2,333,333	A	$15(1)	3,030,983(6)	I	See footnotes(4)(5)
Common Stock, par value $0.0001 per share	07/24/2026		P		50,000	A	$22.31(2)	3,080,983(6)	I	See footnotes(4)(5)
Common Stock, par value $0.0001 per share	07/28/2026		P		7,905	A	$18.25(2)	3,088,888(3)(6)	I	See footnotes(4)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Avoro Capital Advisors LLC

(Last) (First) (Middle)

110 GREENE STREET

SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Avoro Ventures LLC

(Last) (First) (Middle)

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

Explanation of Responses:

1. The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").

2. The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

3. Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.

4. The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

5. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

6. The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

Remarks:

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.

	Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer	07/28/2026
	Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer Chief Compliance Officer	07/28/2026
	/s/ Behzad Aghazadeh	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)